SCHEMBL6043729

SCHEMBL6043729

COC(=O)N1CCN(C(=O)CCO)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.43
KMT2A Q03164 3/20 0.43
HPGD P15428 2/20 0.43
MEN1 O00255 2/20 0.43
USP2 O75604 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
CYP3A4 P08684 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
GLA P06280 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
MAPT P10636 5/20 0.40
CYP2D6 P10635 1/20 0.40
ATM Q13315 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6043723 0.84 ALDH1A1 (0.43) ALDH1A1KMT2AHPGDMEN1USP2
SCHEMBL9723662 0.82
SCHEMBL771244 0.82 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1USP2KDM4E
SCHEMBL20617537 0.80 L3MBTL1 (0.53) ALDH1A1KMT2AMEN1USP2KDM4E
SCHEMBL8603867 0.80
SCHEMBL1873737 0.79 USP2 (0.51) KMT2AHPGDMEN1USP2SMN1; SMN2
SCHEMBL13472660 0.79 ALDH1A1 (0.50) ALDH1A1KMT2AMEN1KDM4ESMN1; SMN2
SCHEMBL27370145 0.78 GNAI3 (0.63) KMT2AMEN1TDP1POLBGLA
SCHEMBL13672766 0.78 ALDH1A1 (0.69) ALDH1A1KMT2AUSP2LMNASMN1; SMN2
SCHEMBL8488022 0.78 ALDH1A1 (0.44) ALDH1A1KMT2AMEN1USP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides ELAN PHARMACEUTICALS, INC. 2006-04-27 US disclosed
US-5641778-A EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1997-06-24 US disclosed
EP-0716077-A1 Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors CIBA-GEIGY AG (CH) 1996-06-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089355-A1 Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides APP, BACE1, BACE2 ALDH1A1 1039/4885KMT2A 2309/4885HPGD 2228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.